Inclusion Criteria:

• Patients who have a diagnosis of acute myeloid leukemia that is relapsed or refractory to standard treatment. A baseline bone marrow assessment is required less than or equal to 72 hours prior to the first dose of study drug.
• Must have greater than or equal to 5% blasts present in peripheral blood at pre-study baseline assessment.
• AML blast cells must express survivin.
• Must have discontinued all previous therapies for cancer at least 30 days (6 weeks for mitomycin-C or nitrosoureas)before study enrollment. Hydroxyurea must be stopped at least 72 hours before study drug administration.
• Must have adequate organ function.
• Females must have a negative pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 6 months following the last dose of study drug.

Exclusion Criteria:

• Have received treatment within the last 30 days with a drug that has not received regulatory approval.
• Patients with acute promyelocytic leukemia (APML).
• Patients with chronic myeloid leukemia (CML) in blast crisis.
• Major surgery within 4 weeks of study enrollment.
• Patients with serious pre-existing medical conditions.
• Patients with known coagulopathy or bleeding disorder, other than leukemia related thrombocytopenia. Patients with severe of life threatening bleeding refractory to platelet transfusions are also excluded.
• Concomitant anticoagulant therapy (with the exception of heparinized saline to maintain the patency of central venous catheters).
• Women who are pregnant or breast feeding.